Pre-order Enquiry
Request Free Sample
Healthcare
Aerospace & Defence
Agriculture
Automations
Chemicals & Advanced Materials
Food & Beverages
Information & Communication Technology
Oil & Gas
Power & Energy
Global Montelukast Intermediate Market: Information by Application (Asthma, Allergic Rhinitis, Bronchospasm and Urticaria) - Forecast till 2023
Market analysis
The Global Montelukast Intermediate Market has been used to prevent wheezing, difficulty in breathing, chest tightness, and coughing caused by asthma by Montelukast which is a leukotriene receptor antagonist (LTRA)The collective presence of generics and the opposing part of the presence of stringent regulatory policies and the tall prices of manufacturing building blocks for active pharmaceutical ingredients which are likely to hamper the market development during the forecast period. Additionally, montelukast is designated for the handling of periodic and recurrent allergic rhinitis. The important aspects pouring the market evolution are worldwide rising commonness of allergic rhinitis, urticaria, asthma, bronchospasm, burgeoning pharmaceutical industry attached with the rising call from active pharmaceutical ingredients (APIs) manufacturers, and montelukast patent expiration.
Market segmentation
The segmentation for Global Montelukast Intermediate Market is given by the influences describing the market progress which are worldwide increasing frequency of allergic rhinitis, and urticaria asthma, bronchospasm mushrooming pharmaceutical industry coupled with the cumulative demand from API manufacturers, and montelukast patent termination along with the snowballing presence of generics. The global montelukast transitional Market is also provided by application which can thus be classified into three types, viz; bronchospasm, and urticaria. asthma and allergic rhinitis. The World Health Organization (WHO) has estimated that 15 million disability-adjusted life-years are gone and 250,000 asthma deaths are informed worldwide every year. In the year 2016, asthma ranked twenty third (global) and thirty-first (in low- and middle-income countries — LMICs) among the foremost causes of premature mortality (YLL). The market development in the European region is mostly due to the existence of huge pharmaceutical companies and sophisticated healthcare substructure and the rising frequency of asthma and allergic rhinitis in the US and Canada. About six million children under the age of 18 have asthma being more mutual in children than adults. Also, one in 13 people is living with asthma and is more common in adult women than adult men. Hence, the swelling burden of asthma is powering the demand for montelukast and is supporting in the market growth.
Regional analysis
Geographically, The Global Montelukast Intermediate Market is segmented and targeted into global regions like Americas, Asia-Pacific, Middle East and Africa along with the European market.
Additionally, North America is expected to lead the market. Furthermore, The Global Montelukast Intermediate Market in the Americas is segmented into North America and Latin America.
It is forecasted that Europe currently holds a substantial share in the global Montelukast Intermediate market. The reasons responsible for the market progress in this region are poor air quality due to high fuel release and is growing the occurrence of chronic obstructive pulmonary disease (COPD), asthma, allergy and in the UK, Germany, and France. The Middle East and Africa market are predictable to hold the minimum share in the global Montelukast Intermediate market. In this region, the Middle East is expected to control due to the presence of countries such as Egypt, Saudi Arabia, and others. Asia-Pacific is likely to characterize a hopeful outlook over the forecast period due to the mounting geriatric population along with the increasing prevalence of respiratory diseases. In Australia, one child out of six under the age of 16 is affected by asthma, while, India has an projected 15 to 20 Million. According to the WHO, presently, there are about 3 Million asthmatics in Japan of whom 7%have severe, and 30% have moderate asthma. The European Respiratory Society stated that, currently, about 30 Million children and adults less than 45 years old have asthma within the UK and Ireland have some of the maximum rates of asthma in the world. In Germany, there are an estimated 4 Million asthmatics. In addition, an article published in the NCBI journal specified that the commonness of allergic diseases in Europe is high.
Major players
Companies like P.G. Shah & Co., Manus Aktteva Biopharma LLP, VIVAN Life Sciences, P.G. Shah & Co. and Ortin Laboratories Limited., etc. are some of the major players in the global Montelukast Intermediate market.
Market analysis
The Global Montelukast Intermediate Market has been used to prevent wheezing, difficulty in breathing, chest tightness, and coughing caused by asthma by Montelukast which is a leukotriene receptor antagonist (LTRA)The collective presence of generics and the opposing part of the presence of stringent regulatory policies and the tall prices of manufacturing building blocks for active pharmaceutical ingredients which are likely to hamper the market development during the forecast period. Additionally, montelukast is designated for the handling of periodic and recurrent allergic rhinitis. The important aspects pouring the market evolution are worldwide rising commonness of allergic rhinitis, urticaria, asthma, bronchospasm, burgeoning pharmaceutical industry attached with the rising call from active pharmaceutical ingredients (APIs) manufacturers, and montelukast patent expiration.
Market segmentation
The segmentation for Global Montelukast Intermediate Market is given by the influences describing the market progress which are worldwide increasing frequency of allergic rhinitis, and urticaria asthma, bronchospasm mushrooming pharmaceutical industry coupled with the cumulative demand from API manufacturers, and montelukast patent termination along with the snowballing presence of generics. The global montelukast transitional Market is also provided by application which can thus be classified into three types, viz; bronchospasm, and urticaria. asthma and allergic rhinitis. The World Health Organization (WHO) has estimated that 15 million disability-adjusted life-years are gone and 250,000 asthma deaths are informed worldwide every year. In the year 2016, asthma ranked twenty third (global) and thirty-first (in low- and middle-income countries — LMICs) among the foremost causes of premature mortality (YLL). The market development in the European region is mostly due to the existence of huge pharmaceutical companies and sophisticated healthcare substructure and the rising frequency of asthma and allergic rhinitis in the US and Canada. About six million children under the age of 18 have asthma being more mutual in children than adults. Also, one in 13 people is living with asthma and is more common in adult women than adult men. Hence, the swelling burden of asthma is powering the demand for montelukast and is supporting in the market growth.
Regional analysis
Geographically, The Global Montelukast Intermediate Market is segmented and targeted into global regions like Americas, Asia-Pacific, Middle East and Africa along with the European market.
Additionally, North America is expected to lead the market. Furthermore, The Global Montelukast Intermediate Market in the Americas is segmented into North America and Latin America.
It is forecasted that Europe currently holds a substantial share in the global Montelukast Intermediate market. The reasons responsible for the market progress in this region are poor air quality due to high fuel release and is growing the occurrence of chronic obstructive pulmonary disease (COPD), asthma, allergy and in the UK, Germany, and France. The Middle East and Africa market are predictable to hold the minimum share in the global Montelukast Intermediate market. In this region, the Middle East is expected to control due to the presence of countries such as Egypt, Saudi Arabia, and others. Asia-Pacific is likely to characterize a hopeful outlook over the forecast period due to the mounting geriatric population along with the increasing prevalence of respiratory diseases. In Australia, one child out of six under the age of 16 is affected by asthma, while, India has an projected 15 to 20 Million. According to the WHO, presently, there are about 3 Million asthmatics in Japan of whom 7%have severe, and 30% have moderate asthma. The European Respiratory Society stated that, currently, about 30 Million children and adults less than 45 years old have asthma within the UK and Ireland have some of the maximum rates of asthma in the world. In Germany, there are an estimated 4 Million asthmatics. In addition, an article published in the NCBI journal specified that the commonness of allergic diseases in Europe is high.
Major players
Companies like P.G. Shah & Co., Manus Aktteva Biopharma LLP, VIVAN Life Sciences, P.G. Shah & Co. and Ortin Laboratories Limited., etc. are some of the major players in the global Montelukast Intermediate market.
Frequently Asked Questions
This market study covers the global and regional market with an in-depth analysis of the overall growth prospects in the market. Furthermore, it sheds light on the comprehensive competitive landscape of the global market. The report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts.
- By product type
- By End User/Applications
- By Technology
- By Region
The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing.
